MediClin AG, DE0006595101

MediClin AG, DE0006595101

05.11.2018 - 15:39:39

MEDICLIN is satisfied with the business development of the first nine months of 2018

Offenburg, 5 November 2018

MEDICLIN is satisfied with the business development of the first nine months of 2018

MEDICLIN could increase its Group sales by 7.2% or EUR 32.7 mill. due to capacity expansions and a rise in number of cases. Compared to the previous year's period about 450 more employees are working for the Company. The Group operating result is slightly below prior year due to a positive one-off effect in 2017. Outlook confirmed.

In the first nine months of the 2018 financial year, MEDICLIN Aktiengesellschaft (MEDICLIN) was able to raise Group sales by 7.2 % year-on-year or EUR 32.7 mill. to EUR 485.2 mill. Sales growth was mostly driven by capacity expansions and increases in the number of cases. The post-acute segment contributed to sales growth the largest share of EUR 22.6 mill. The acute segment accounted for EUR 9.3 mill.

The Group operating result decreased by EUR 1.6 mill. compared to the previous year, from EUR 19.4 mill. to EUR 17.8 mill. The previous year's Group EBIT includes a one-off effect of EUR 5.7 mill. from the revaluation of assets from an acquisition. Adjusted for this one-off effect, Group EBIT improved by EUR 4.1 mill.

Gratifying business development in the post-acute and acute segments

Sales in the post-acute segment increased by EUR 22.6 mill. (+8.1 %) up to EUR 300.5 mill. The acute segment could raise its sales by EUR 9.3 (+5.8 %) up to EUR 169.2 mill. Sales of the nursing care business area were at the prior year's level. In the post-acute segment EBIT increased by EUR 4.3 mill. up to EUR 19.1 mill. In the acute segment EBIT improved by EUR 2.5 mill. up to EUR 1.6 mill.

MEDICLIN expects to reach the guidance for 2018

In the fourth quarter of the 2018 financial year, the Management Board expects a similar business performance as in the previous quarters. It assumes that the sales growth guidance for 2018 will be reached for the Group. Group EBIT are expected to be at the lower end of the guidance.

High investments in further growth

In the first nine months of 2018 gross investments amounted to EUR 32.2 mill (9M 2017: 35.9 mill.), pertaining mainly to the reconstruction and expansion of clinics and the acquisition of medical equipment. Capital expenditure is thus in line with the annual budget. Cash and cash equivalents as of 30 September 2018 amounted to EUR 46.6 mill. (31.12.2017: EUR 26.9 mill.).

Number of employees increased significantly

MEDICLIN employs on average 443 more employees compared to the previous year's period due to capacity expansions in the Group. Calculated in full-time employees it means that on average 288 more full-time employees are employed. Also the number of trainees increased on average from 270 trainees to 293 trainees in the Group. The overall headcount is about 10,000.

New construction of a hospital in Lingen

Currently the largest project of MEDICLIN is the construction of a new clinic for neurology, neurointensive care and neurophysiology at the location of MediClin Hedon Klinik in Lingen. The construction costs of this new hospital will amount to about EUR 30.0 mill. The German federal state of Lower Saxony will subsidise this investment under the hospital financing law (Krankenhausfinanzierungsgesetz - KHG) and contributes EUR 20.0 mill. Thus, MEDICLIN consequently continues its strategy of internal growth within the Group.

Enhancement of the Supervisory Board to 16 members

In the future MEDICLIN will employ more than 10,000 employees therefore the Management Board has initiated a status proceeding regarding the composition of the Supervisory Board mid of October. So far the Supervisory Board consists of six shareholder representatives and six employee representatives. A board of 16 members is required if a co-determined company has generally more than 10,000 employees.

The interim report as of 30 September 2018 is available on the homepage of MEDICLIN in German and English. www.mediclin.de

 

About MEDICLIN AG (Ticker: MED; WKN: 659 510)

MEDICLIN owns 36 clinics, seven nursing care facilities, three home nursing care services and nine medical care centres. The Group has about 8,300 beds and a headcount of about 10,000. With its strong network, MEDICLIN can offer its patients integrated care from the first visit to the doctor to surgery, post-operative rehabilitation and follow-up care at home. Doctors, therapists and nurses work together closely to achieve the best results. MEDICLIN plans the care of persons in need in accordance with their individual requirements and personal needs, either at home or in a nursing care facility.

MEDICLIN - A company of the Asklepios Group

05.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg

Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

741329  05.11.2018 

@ dgap.de